The project is based on the development of the Siberian Branch of the Russian Academy of Sciences
Research groundwork
Inhalation delivery technologies have been developed at the institutes of the Siberian Branch of the Russian Academy of Sciences since the 80s of the XX century. In the early 2000s, as part of integration projects of several leading institutions, technologies were refined for use in healthcare.

The objective of the research was to find the optimal parameters to reduce toxicity and increase the bioavailability of active medicinal substances. To do this, a mathematical model of the human respiratory tract was created and the optimal particle size to ensure the maximum delivery of the active substance to various parts of the lungs was determined.

The next task was to ensure a high concentration, stability and continuous delivery of the generated aerosol. This task was also solved. Currently, the created working laboratory samples generate a stable aerosol with a high concentration during the entire inhalation session. As a result, a set of factors influencing the field of physical quantities was formed, which are subject to control during the development of the optimal aerosol generation mode for each specific active substance.

Our company received the rights and, together with the institutes of the SB RAS, adapted a set of technologies that by several times increase the efficiency of existing inhalers and significantly expand the market for their use. These technologies improve the inhalation administration of drugs and provide monitoring of the entire inhalation procedure.
Various aerosol technologies
Particle size control and aerosol stability maintenance
Calculation of the administered dose
aerosol generation
Customized treatment due to digital services
PM&HM inhalers
Ultrasound inhalers
Limited, available
in some models
Compressor inhalers
Powder inhalers
Limited, available
in some models
Dispensing inhalers
Limited, available
in some models
Research results
The current results allowed us to launch a unique product with strong competitive advantages:
The stability of particle size and concentration of 80% aerosol in the range of +/- 10% of the specified value of the particle size (for each drug, the particle size is determined to ensure the maximum delivery efficiency).

Accurate calculation of the dose administered.

Confirmation of the fact of administration of the exact dose of a specific drug by a specific patient (digital control of treatment).

Higher efficiency of local drug delivery with PM&HM technologies compared to existing inhalers.

Both local and systemic effect of drugs delivered with controlled aerosols.

Reduced therapeutic dose when delivered through inhalation with PM&HM technologies required for a comparable concentration of the active substance in the systemic circulation upon oral administration.

Higher efficiency of inhaled drug delivery with PM&HM technologies in comparison with oral administration of tablet dosage form.

A significant reduction in side effects during inhalation delivery of drugs with PM&HM technologies in comparison with oral administration of tablet dosage form.

Application of platform technologies for a wide range of drugs.
A complete R&D portfolio of the company with the necessary list of research protocols and primary information can be provided upon request.
Technological prospects
of the project
- Reduction of the dose of the prescribed drug by the doctor for topical use, which will reduce the toxicological burden on the patient.

- Accurate calculation of the dose received by the patient. Confirmation of administration.
Increase the efficiency of inhalation delivery in the local treatment of pulmonary diseases in comparison with existing nebulizers
- Increase in the bioavailability of inhaled drugs in comparison with the tablet dosage form.

- Treatment of various types of diseases with a significant reduction in side effects by reducing the dose.

- Delivery of drugs with an immediate or prolonged effect.
Deliver drugs to the systemic circulation and manage the pharmacokinetic profile.
We are currently working on several technology application strategies:
Compatible drugs
Prerequisites and opportunities
Implementation of project technologies into existing treatment standards for various diseases (local application)
- Iloprost (pulmonary hypertension)
- Tobramycin (cystic fibrosis)
- Budesonide (asthma, COPD)
- Salbutamol (asthma, COPD)
- Beclometasone (asthma, COPD)
- Fenoterol (asthma, COPD)
- Formoterol (asthma, COPD)
- Tiotropium bromide (asthma, COPD)
- Ipratropium bromide (asthma, COPD)
1.1. Traditional application of inhalation technologies. Quick registration of targeted drugs (change of primary packaging).
1.2. Significantly improved efficiency of inhalation delivery.
1.3. Full control over the treatment process for doctors.
Application of project technologies for the treatment of COVID-19 pneumonia
(topical application with additional systemic effect)

- Antispasmodics (Ipratropium bromide and Fenoterol, Budesonide, Salbutamol)
- Mucolytics (Ambroxol, Acetylcysteine)
- Antibiotics (Tobramycin, Gentamicin, Amikacin and other antibiotics in the form of solutions for inhalation)
2.1. Insufficient efficacy of oral drugs and a decrease in the delivery efficiency of injectable drugs.
2.2. Low efficiency of the existing inhalation technologies due to the deposition of aerosols in the upper respiratory tract.
2.3. The need for medical personnel to monitor delivery and calculate the dose administered.
Introduction of technology into tuberculosis treatment standards
(systemic application)

- First- and second-line soluble drugs
- Fluoroquinolones
- Aminoglycosides
3.1. The need to reduce toxicity, confirm the fact of administration and the dose of each drug.
3.2. Support of the World Health Organization and the international expert community.
3.3. Successful preclinical trials of anti-tuberculosis drugs.
Koch-Mechnikov - Resolution
March 20, 2018, Berlin, a "New developments, nanotechnology" section was held, organized by our company, as part of the 13th Scientific Symposium on the occasion of World Tuberculosis Day 2019.

The section was moderated by Dr. T. Ulrichs, (Koch-Mechnikov Forum, Berlin), Dr. W. Jakubowiak, (WHO Medical Consultant, Geneva), T. Othmer, (DZK, Berlin), and A. Melnikov (PM&HM, Moscow)

The section discussed the introduction of PM&HM technologies in the treatment of tuberculosis in the world.
The project's technology-related articles and publications